Evogene price target raised to $6 from $1 at Roth MKM

Roth MKM raised the firm’s price target on Evogene (EVGN) to $6 from $1 and keeps a Buy rating on the shares. The company has made significant progress in commercialization of its Casterra and Lavie Bio business units, the analyst tells investors in a research note. The firm further cites Evogene having announced the signing of an exclusive distribution agreement with Corteva (CTVA) this week to further develop and market its leading biofungicide product candidate LAV311/312, which targets Botrytis.